- Home
- PROK vs LXRX Comparison
PROK vs LXRX Comparison
Compare PROK & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- LXRX
- Stock Information
- Founded
- PROK 2015
- LXRX 1995
- Country
- PROK United States
- LXRX United States
- Employees
- PROK N/A
- LXRX N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- PROK Health Care
- LXRX Health Care
- Exchange
- PROK Nasdaq
- LXRX Nasdaq
- Market Cap
- PROK 384.2M
- LXRX 428.8M
- IPO Year
- PROK N/A
- LXRX 2000
- Fundamental
- Price
- PROK $2.17
- LXRX $1.07
- Analyst Decision
- PROK Buy
- LXRX Buy
- Analyst Count
- PROK 5
- LXRX 5
- Target Price
- PROK $6.25
- LXRX $3.23
- AVG Volume (30 Days)
- PROK 1.7M
- LXRX 1.9M
- Earning Date
- PROK 08-12-2025
- LXRX 08-06-2025
- Dividend Yield
- PROK N/A
- LXRX N/A
- EPS Growth
- PROK N/A
- LXRX N/A
- EPS
- PROK N/A
- LXRX N/A
- Revenue
- PROK $527,000.00
- LXRX $58,432,000.00
- Revenue This Year
- PROK $265.05
- LXRX N/A
- Revenue Next Year
- PROK N/A
- LXRX N/A
- P/E Ratio
- PROK N/A
- LXRX N/A
- Revenue Growth
- PROK N/A
- LXRX 1504.83
- 52 Week Low
- PROK $0.46
- LXRX $0.28
- 52 Week High
- PROK $7.13
- LXRX $2.18
- Technical
- Relative Strength Index (RSI)
- PROK 41.52
- LXRX 45.39
- Support Level
- PROK $2.23
- LXRX $1.03
- Resistance Level
- PROK $2.44
- LXRX $1.11
- Average True Range (ATR)
- PROK 0.15
- LXRX 0.06
- MACD
- PROK -0.02
- LXRX -0.01
- Stochastic Oscillator
- PROK 6.07
- LXRX 17.50
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.